Compare Medpace Holdings Inc (MEDP) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Prudential PLC — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Prudential PLC is the larger of the two by market cap, and Prudential PLC pays a 2.33% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Prudential PLC for 119 Days on average.
| MEDP | PUK | |
|---|---|---|
Market Cap | $16.82B | $28.84B |
Volume | 223,093 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $630.19 | $33.61 |
52-Week Low | $393.42 | $23.54 |
Typical Hold Time | 14 Days | 119 Days |
Enterprise Value | $16.44B | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Prudential (PUK) trades at $23.87, up 1.38% with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company demonstrates strong revenue growth from $16.2B in 2024 to $27.4B in 2025, with consistent profitability margins above 12%. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while implementing a $3 billion capital rotation plan.
The outlook remains cautiously optimistic with 50% analyst buy ratings, though technical indicators suggest near-term pressure. Key risks include execution of strategic transitions and emerging market exposure reductions. The stock presents value characteristics with an 8.4 P/E ratio while maintaining dividend distributions, though investors should monitor earnings consistency after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
